Ruxolitinib for treatment of polycythemia vera and myelofibrosis in patients after liver transplantation

Although ruxolitinib contributes to immunomodulation and can lead to severe infections, it seems a feasible treatment strategy for patients with polycythemia vera and myelofibrosis after liver transplantation. Patients after liver transplantation have an increased risk to develop hematologic neoplasia. Information how to treat these patients in the context of immunosuppression is sparse. Here, we report two patients with polycythemia vera (PV) and myelofibrosis (MF) on ruxolitinib after liver transplantation.